50 mg/g, cream
Aciclovirum
Zovirax Intensive and Acevirex are different trade names for the same medicine.
important information for the patient.
This medicine should always be used exactly as described in the patient leaflet or according to the
recommendations of a doctor, pharmacist, or nurse.
Zovirax Intensive cream for topical use contains the active substance acyclovir with antiviral action, showing strong action against the herpes simplex virus (Herpes simplex).
Zovirax Intensive cream is indicated for the local treatment of recurrent herpes of the lips and face, caused by the herpes simplex virus Herpes simplex.
Zovirax Intensive should only be used on herpes located on the lips and face.
You should avoid contact of the medicine with the eyes.
In case the medicine gets into the eyes, they should be rinsed thoroughly with warm water. In case of doubt, you should consult a doctor.
Before and after applying the medicine, you should wash your hands to prevent the transmission of the infection to other areas of the skin. During treatment, you should not scratch the blisters or crusts or touch them with a towel.
To limit the risk of transmitting the infection to other people, you should not let them touch the herpetic skin lesions, use shared towels, etc.
You should tell your doctor or pharmacist about all the medicines you are taking or have recently taken, as well as the medicines you plan to take. Interactions of Zovirax Intensive with other medicines are not known.
In pregnancy and during breastfeeding, or if you think you may be pregnant or plan to become pregnant, you should consult a doctor or pharmacist before using this medicine.
Zovirax Intensive has no influence or negligible influence on the ability to drive and use machines.
Zovirax Intensive contains 400 mg of propylene glycol in each gram of cream.
Due to the presence of the excipient propylene glycol, the medicine may cause skin irritation.
This medicine should not be used in children under 4 weeks of age, on open wounds or large areas of damaged or broken skin (e.g., burned), without consulting a doctor or pharmacist.
Zovirax Intensive contains 7.5 mg of sodium lauryl sulfate in each gram of cream.
Sodium lauryl sulfate may cause local skin irritation (such as stinging or burning) or exacerbate skin reactions caused by other medicines used on the same skin area.
Patients with impaired skin barrier, e.g., atopic dermatitis, are more sensitive to the irritating properties of sodium lauryl sulfate.
Due to the presence of the excipient cetearyl alcohol, the medicine may cause a local skin reaction (e.g., contact dermatitis).
This medicine should always be used exactly as described in the patient leaflet or according to the recommendations of a doctor, pharmacist, or nurse. If in doubt, you should consult a doctor, pharmacist, or nurse.
Zovirax Intensive cream is intended for topical use. Usually, unless the doctor recommends otherwise, the medicine is used as described below.
The medicine should be applied 5 times a day to the affected areas of the skin at approximately 4-hour intervals, with a night break. The medicine works best if treatment is started as soon as possible after the first symptoms of herpes appear, such as burning, itching, or redness. Treatment can also be started later, when bumps or blisters appear.
Treatment should be continued for at least 4 days.
If the skin lesions have not healed, treatment can be extended to 10 days. If the skin lesions do not disappear after 10 days of using the medicine, you should consult a doctor.
To prevent the worsening or transmission of the infection, you should wash your hands before and after applying the medicine, and also avoid unnecessary rubbing of the affected areas or touching them with a towel.
If you feel that the effect of the medicine is too strong or too weak, you should consult a doctor.
No toxic symptoms should occur, even after accidental ingestion of the entire contents of the Zovirax Intensive tube. However, in case of swallowing a large amount of cream, you should contact a doctor or pharmacist.
You should not use a double dose to make up for a missed dose. If you miss a dose, you should apply the cream as soon as you remember and continue treatment as before.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may occur:
Uncommon(may affect up to 1 in 100 people)
If you experience any side effects, including any possible side effects not listed in this leaflet, you should inform your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder or parallel importer.
Reporting side effects will help to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Store in a temperature below 25°C in the original packaging. Do not store in the refrigerator.
Do not use this medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The medicine is a white cream in an aluminum tube in a cardboard box.
The packaging contains 5 g of cream.
For more detailed information, you should contact the marketing authorization holder or parallel importer.
GlaxoSmithKline (Ireland) Limited
12 Riverwalk, Citywest Business Campus
Dublin 24
Ireland
GlaxoSmithKline Trading Services Limited
12 Riverwalk, Citywest Business Campus
Dublin 24, D24 YK11
Ireland
Allpharm Sp. z o.o. sp.k.
ul. M. Zdziechowskiego 11/4
02-659 Warsaw
CEFEA Sp. z o.o. Sp.
komandytowa
ul. Działkowa 56
02-234 Warsaw
Synoptis Industrial Sp. z o.o.
ul. Forteczna 35-37
87-100 Toruń
Shiraz Productions Sp. z o.o.
ul. Tymiankowa 24/28
95-054 Ksawerów
Authorization number in Romania, the country of export:10459/2017/01
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.